<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966289</url>
  </required_header>
  <id_info>
    <org_study_id>J13138</org_study_id>
    <secondary_id>NA_00087578</secondary_id>
    <nct_id>NCT01966289</nct_id>
  </id_info>
  <brief_title>SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)</brief_title>
  <official_title>A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Therapeutics, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Susan Cohan Colon Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at whether CY/GVAX in combination with SGI-110 is effective
      (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe
      in patients with metastatic colon or rectum cancers.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in CD45RO+ tumor infiltrating lymphocytes (TILs) measured by immunohistochemistry in pre and post-treatment tumor biopsies from patients with metastatic colorectal cancer</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1:CY/GVAX concurrently with SGI-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CY/GVAX after SGI-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: CY/GVAX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: SGI-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY</intervention_name>
    <description>CY is administered intravenously at 200 mg/m2</description>
    <arm_group_label>Cohort 1:CY/GVAX concurrently with SGI-110</arm_group_label>
    <arm_group_label>Cohort 2: CY/GVAX after SGI-110</arm_group_label>
    <arm_group_label>Cohort 3: CY/GVAX</arm_group_label>
    <other_name>Cyclophosphamide, Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GVAX</intervention_name>
    <description>GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells</description>
    <arm_group_label>Cohort 1:CY/GVAX concurrently with SGI-110</arm_group_label>
    <arm_group_label>Cohort 2: CY/GVAX after SGI-110</arm_group_label>
    <arm_group_label>Cohort 3: CY/GVAX</arm_group_label>
    <other_name>Colon cancer tumor vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGI-110</intervention_name>
    <description>SGI-110 is administered subcutaneously at 60 mg/m2</description>
    <arm_group_label>Cohort 1:CY/GVAX concurrently with SGI-110</arm_group_label>
    <arm_group_label>Cohort 2: CY/GVAX after SGI-110</arm_group_label>
    <arm_group_label>Cohort 4: SGI-110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Documented cancer of the colon or rectum who have received and are stable on first or
             second-line therapy regimens for metastatic colorectal cancer

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

          3. Adequate organ function as defined by study-specified laboratory tests

          4. Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

          5. Signed informed consent form

          6. Willing and able to comply with study procedures

        Exclusion Criteria:

          1. Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, immune or other medical conditions

          2. Systemically active steroid use

          3. Another investigational product within 28 days prior to receiving study drug

          4. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring
             within 28 days prior to receiving study drug

          5. Chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior
             to receiving study drug

          6. Pregnant or lactating

          7. Unwilling or unable to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Neoplasms</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Rectal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Guadecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

